209 related articles for article (PubMed ID: 9116717)
1. Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice.
Burny W; Lebrun P; Cosyns JP; Saint-Remy JM
Lupus; 1997; 6(1):4-17. PubMed ID: 9116717
[TBL] [Abstract][Full Text] [Related]
2. Injections of complexes made of dsDNA and specific polyclonal antibodies extend MRL lpr mouse survival: a pilot study.
Lebrun P; Burny W; Cosyns JP; Saint-Remy JM
Lupus; 1994 Feb; 3(1):47-53. PubMed ID: 8025586
[TBL] [Abstract][Full Text] [Related]
3. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice.
Fenton KA; Tømmerås B; Marion TN; Rekvig OP
Autoimmunity; 2010 Mar; 43(2):179-88. PubMed ID: 19835488
[TBL] [Abstract][Full Text] [Related]
4. High titer anti-basement membrane antibodies in a subset of patients with pediatric systemic lupus erythematosus.
Orjuela A; Suwanichkul A; Canter D; Minard CG; Devaraj S; Hicks MJ; Muscal E; Wenderfer SE
Am J Nephrol; 2015; 41(3):241-7. PubMed ID: 25926050
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential.
Zhao Z; Weinstein E; Tuzova M; Davidson A; Mundel P; Marambio P; Putterman C
Arthritis Rheum; 2005 Feb; 52(2):522-30. PubMed ID: 15693007
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus.
Jørgensen MH; Rekvig OP; Jacobsen RS; Jacobsen S; Fenton KA
Immunol Lett; 2011 Aug; 138(2):179-86. PubMed ID: 21530588
[TBL] [Abstract][Full Text] [Related]
7. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
8. The effects of anti-idiotypic antibody on antibody production and apoptosis of anti-dsDNA antibody producing cells.
Lee CH; Suh CH; Lee J; Kim YT; Lee SK
Clin Exp Rheumatol; 2003; 21(3):291-300. PubMed ID: 12846046
[TBL] [Abstract][Full Text] [Related]
9. IgM antibodies against dsDNA in SLE.
Witte T
Clin Rev Allergy Immunol; 2008 Jun; 34(3):345-7. PubMed ID: 18097774
[TBL] [Abstract][Full Text] [Related]
10. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.
Spertini F; Leimgruber A; Morel B; Khazaeli MB; Yamamoto K; Dayer JM; Weisbart RH; Lee ML
J Rheumatol; 1999 Dec; 26(12):2602-8. PubMed ID: 10606369
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
Jonsson CA; Svensson L; Carlsten H
Clin Exp Immunol; 1999 Jun; 116(3):534-41. PubMed ID: 10361247
[TBL] [Abstract][Full Text] [Related]
12. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
14. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
15. [Role of the nucleosome in the physiopathology of systemic lupus erythematosus].
Amoura Z; Piette JC
Ann Med Interne (Paris); 2003 Feb; 154(1):25-32. PubMed ID: 12746656
[TBL] [Abstract][Full Text] [Related]
16. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis.
Kalaaji M; Sturfelt G; Mjelle JE; Nossent H; Rekvig OP
Arthritis Rheum; 2006 Mar; 54(3):914-26. PubMed ID: 16508974
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactivity of antiidiotypic antibodies with DNA in systemic lupus erythematosus.
Eivazova ER; McDonnell JM; Sutton BJ; Staines NA
Arthritis Rheum; 2000 Feb; 43(2):429-39. PubMed ID: 10693885
[TBL] [Abstract][Full Text] [Related]
18. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
19. [Immunology in medical practice. III. Disseminated lupus erythematosus: disturbed apoptosis?].
Berden JH
Ned Tijdschr Geneeskd; 1997 Sep; 141(39):1848-54. PubMed ID: 9545742
[TBL] [Abstract][Full Text] [Related]
20. Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti-dsDNA antibodies in (NZBxNZW)F1 mice.
Mjelle JE; Kalaaji M; Rekvig OP
Autoimmunity; 2009 Feb; 42(2):104-11. PubMed ID: 19005880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
